Several oral CCR1 antagonists had been developed for immunologically mediated inflammatory diseases such as RA, multiple sclerosis, and chronic obstructive pulmonary disease.[60–62] CCX354-C is a small molecule CCR1 antagonist that inhibits CCR1-dependent signaling, including chemotaxis. Here, CCR1 is linked to chronic obstructive pulmonary disease.